Core Viewpoint - Beijing Northland Biotechnology Co., Ltd. has revised its related party transaction management system to ensure fairness, transparency, and protection of the rights of non-related shareholders, in compliance with relevant laws and regulations [1][2]. Section Summaries Chapter 1: General Principles - The purpose of the revised system is to ensure that related party transactions are conducted fairly and do not harm the interests of the company and non-related shareholders [2]. Chapter 2: Related Parties and Relationships - Related parties include both legal entities and natural persons that have significant control or influence over the company [3][4]. - The criteria for identifying related parties include ownership stakes, control relationships, and significant influence in financial and operational decisions [4][5]. Chapter 3: Related Transactions - Related transactions encompass various activities such as asset purchases, investments, guarantees, financial assistance, and management contracts [8][9]. - Transactions must adhere to principles of honesty, equality, and fairness, ensuring that they do not harm the interests of the company or its non-related shareholders [9][10]. Chapter 4: Decision-Making Authority and Review Procedures - Transactions exceeding 2% of the company's total audited assets or 30 million yuan require shareholder meeting approval, along with an assessment report [7]. - The board of directors must review transactions that meet specific thresholds, ensuring independent directors are involved in the decision-making process [7][8]. Chapter 5: Miscellaneous Provisions - The management system will take effect upon approval by the shareholders' meeting, and the board of directors is responsible for its interpretation [18].

Core Viewpoint - Beijing Northland Biotechnology Co., Ltd. has revised its Commitment Management System to enhance the regulation of commitments made by controlling shareholders, actual controllers, related parties, and other committers, ensuring the protection of minority investors' rights [1][2]. Chapter Summaries Chapter 1: General Principles - The revised system aims to strengthen the regulation of commitments made by the company and its related parties, in accordance with relevant laws and regulations [2]. Chapter 2: Commitment Management - Committers must provide clear performance deadlines for commitments related to stock issuance, refinancing, mergers, and other governance activities, ensuring compliance with industry policies [2][3]. - Committers are required to analyze the feasibility of commitments before making them and disclose any necessary approvals from regulatory authorities [2]. - Commitments must be specific, clear, and actionable, and the company is responsible for timely disclosure of these commitments [2][3]. Chapter 3: Rights and Obligations of Committers - Committers must adhere to their commitments and cannot change or waive them without valid reasons [4]. - Committers can change or waive commitments only under specific circumstances, such as changes in laws or natural disasters [4][5]. - The company must disclose reasons for any changes or waivers of commitments and seek shareholder approval for such changes [5]. Chapter 4: Supplementary Provisions - The system will be implemented after approval by the company's shareholders and will be interpreted by the board of directors [6].

Core Points - The company held its 22nd meeting of the 6th Board of Directors on September 1, 2025, where it approved the proposal to revise the "Rules of Procedure for Board Meetings," which will be submitted for shareholder approval [1][2]. Summary by Sections Chapter 1: General Provisions - The rules aim to standardize the board's decision-making processes and enhance operational efficiency in accordance with relevant laws and regulations [1]. - The board consists of 9 directors, including 3 independent directors and 6 non-independent directors, with one chairman [2]. Chapter 2: Convening the Board - The board must hold at least 2 regular meetings annually, with the chairman responsible for convening and notifying directors at least 10 days in advance [2][3]. - Directors can propose temporary meetings under specific conditions, such as requests from shareholders or a third of the directors [3]. Chapter 3: Conducting Board Meetings - Meetings must follow established procedures, with adequate notice and materials provided to all directors [3][4]. - A quorum requires more than half of the directors to be present, and the chairman leads the meeting [5][6]. Chapter 4: Voting and Decision-Making - Voting is conducted by a show of hands, written ballot, or electronic means, with each director having one vote [9][10]. - Decisions require a majority of votes from present directors, and related-party transactions must be abstained from by interested directors [10][11]. Chapter 5: Documentation and Record-Keeping - The board secretary is responsible for maintaining accurate records of meetings, including attendance, agenda, and voting results [12][13]. - Meeting records must be preserved for at least 10 years, and confidentiality regarding sensitive decisions is mandated [13][14].

证券代码：430047 证券简称：诺思兰德 公告编号：2025-067 北京诺思兰德生物技术股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.08： 《修订〈独立董事专门会 议工作制度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总则 第一条 为完善、规范和保障北京诺思兰德生物技术股份有限公司（以下简 称"公司"）独立董事的权利和义务，充分发挥独立董事作用，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、《上市公司独立董事管理办法》《北 京证券交易所股票上市规则》（以下简称"《上市规则》"）《北京证券交易所上市 公司持续监管指引第 1 号—独立董 ...

Core Viewpoint - The company has approved a new compensation management system for its directors and senior management to enhance motivation and operational efficiency, pending shareholder approval [1][2]. Chapter Summaries Chapter 1: General Principles - The purpose of the new compensation management system is to establish an effective incentive and restraint mechanism for the company's directors and senior management, in accordance with relevant laws and regulations [1]. Chapter 2: Compensation Management Structure - The Compensation and Assessment Committee of the Board is responsible for formulating compensation plans and overseeing the performance evaluation of directors and senior management [2]. - The shareholders' meeting will review the compensation assessment system for directors, while the Board will review that for senior management [2]. Chapter 3: Compensation Standards and Payment Methods - Internal directors receive compensation based on their management roles, while external directors receive an annual allowance [3]. - Independent directors receive an annual allowance and are reimbursed for travel and other reasonable expenses incurred while performing their duties [4]. - Senior management compensation consists of a base salary, performance-based pay, and year-end bonuses, with specific criteria for each component [4][5]. - Compensation adjustments for directors and senior management will be based on industry salary trends, inflation, company performance, and other relevant factors [5]. Chapter 4: Supplementary Provisions - In case of conflicts between this system and existing laws or the company's articles of association, the latter will prevail [5]. - The system will take effect upon approval by the shareholders' meeting [5].

Core Viewpoint - The company has revised its external investment management system to enhance the management and supervision of its investment activities, aiming to control investment risks and improve returns for the company and its shareholders [1][2]. Chapter Summaries Chapter 1: General Principles - The purpose of the revised system is to strengthen the management of external investments, standardize investment behaviors, and protect the interests of the company and its shareholders [2]. - External investments are defined as activities where the company invests monetary funds, equity, and other assets to obtain future returns [2]. Chapter 2: Approval Authority and Organizational Management - The decision-making bodies for external investments include the shareholders' meeting, the board of directors, and the general manager's office, each with specific approval thresholds [5]. - Investments exceeding 50% of the latest audited total assets or 50% of audited annual revenue over 50 million yuan require board and shareholder approval [5][6]. Chapter 3: Implementation and Management of External Investments - The company must develop an implementation plan for external investments, detailing funding amounts, methods, and responsible personnel [6]. - The general manager is responsible for the overall planning and monitoring of investment projects, reporting progress to the board [6]. Chapter 4: Transfer and Recovery of External Investments - The transfer and recovery of external investments must be approved by the appropriate internal authorities [7]. - The company can recover investments under specific circumstances, such as project failure or bankruptcy [8]. Chapter 5: Supervision and Inspection - The audit department is tasked with establishing a supervision and inspection system for internal controls related to external investments [8]. - Any violations leading to investment losses will result in investigations and potential penalties for responsible parties [8]. Chapter 6: Supplementary Provisions - The revised system will take effect after approval by the shareholders' meeting and will be interpreted by the board of directors [11].

证券代码：430047 证券简称：诺思兰德 公告编号：2025-070 北京诺思兰德生物技术股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.11： 《制定〈会计师事务所选 聘制度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总 则 第一条 为规范北京诺思兰德生物技术股份有限公司（以下简称"公司"）选 聘（含续聘、改聘）会计师事务所的行为，切实维护股东利益，提高财务信息质 量，根据《中华人民共和国公司法》 《中华人民共和国证券法》 《国有企业、上市 公司选聘会计师事务所管理办法》等有关法律、法规、规范性文件以及《北京诺 思兰德生物技术股份有限公司公司章程》 ...

Core Viewpoint - Beijing Northland Biotechnology Co., Ltd. has revised its external guarantee management system to regulate external guarantees, control risks, and ensure asset safety, which will be submitted for shareholder approval [1][2]. Chapter Summaries Chapter 1: General Principles - The purpose of the external guarantee management system is to standardize the company's external guarantee behavior and reduce risks [2]. - External guarantees include those provided to subsidiaries, and the total amount of guarantees must be managed uniformly [2][3]. - Guarantees must adhere to principles of legality, prudence, mutual benefit, and risk control [2]. Chapter 2: Approval Authority for External Guarantees - External guarantees require board approval, with specific cases needing shareholder approval, such as guarantees exceeding 10% of the latest audited net assets [3][4]. - Guarantees for related parties must have reasonable commercial logic and require approval from non-related directors [5]. Chapter 3: Approval Procedures for External Guarantees - Guarantees must be approved by the board or shareholders, and unauthorized signing of guarantee contracts is prohibited [6]. - The board must analyze the debtor's credit status and the risks involved before approving guarantees [10]. Chapter 4: Daily Management of External Guarantees - Written contracts must be established for approved guarantees, detailing the scope and duration of the guarantee [9]. - The company must monitor the financial status of the guaranteed party and report any significant changes to the board [9]. Chapter 5: Information Disclosure of External Guarantees - The company must disclose external guarantees in accordance with legal requirements, including total guarantee amounts and their relation to net assets [10][11]. - Any changes in the guaranteed party's debt repayment status must be reported promptly [11]. Chapter 6: Accountability - Directors must adhere to the management system and bear responsibility for any losses from improper guarantees [10]. - The board must take protective measures if losses occur due to the failure of related parties to repay debts [11].

Core Viewpoint - The company has established a subsidiary management system to enhance governance and control over its subsidiaries, ensuring sustainable development and compliance with relevant laws and regulations [1][2]. Chapter Summaries Chapter 1: General Principles - The management system aims to strengthen the company's control over its subsidiaries and improve governance levels [1]. - The term "subsidiary" refers to companies that are included in the company's consolidated financial statements and are controlled by the company [2]. Chapter 2: Governance and Operations of Subsidiaries - Subsidiaries must adhere to the governance structure as per the Company Law and other relevant regulations [2]. - The operation of shareholders' meetings, boards of directors, and supervisory boards in subsidiaries must comply with legal and regulatory requirements [2]. - The company exercises shareholder rights through the subsidiary's shareholders' meeting, including the nomination and election of directors and supervisors [2]. Chapter 3: Management Principles for Subsidiaries - The system is designed to establish effective control mechanisms for the organization, resources, assets, investments, and operations of subsidiaries [3]. - The company is responsible for guiding, supervising, and providing services to its subsidiaries [3]. - Subsidiaries must report significant business and financial matters to the company in a timely manner [4]. Chapter 4: Management of Major Matters and Information Disclosure - Subsidiaries must report any external guarantee matters to the company before proceeding [4]. - Major external guarantees must follow the company's approval procedures [4]. - Subsidiaries are required to establish management systems for the use of raised funds and comply with the company's fundraising management regulations [4]. Chapter 5: Internal Audit Supervision - The company will conduct regular or irregular audits of its subsidiaries [5]. - Subsidiaries must cooperate with the audit process and prepare for audits as required [5]. Chapter 6: Supplementary Provisions - The management system will be executed in accordance with national laws and regulations, and the company's articles of association [6]. - The board of directors is responsible for the formulation and interpretation of this system [6]. - The system will take effect from the date of approval by the board of directors [6].

证券代码：430047 证券简称：诺思兰德 公告编号：2025-073 北京诺思兰德生物技术股份有限公司累积投票实施细则 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.14： 《北京证券交易所股票上市规则》等相关法律、法 规、规范性文件和《北京诺思兰德生物技术股份有限公司章程》 （以下简称"《公 司章程》"）的规定，制定本实施细则。 第二条 本实施细则所称累积投票制，是指公司股东会在选举董事时采用的 一种投票方式。即公司选举董事时，有表决权的每一股份拥有与应选董事人数相 同的表决权，股东拥有的表决权可以集中使用。 《制定〈累积投票实施细 则〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股 ...